KR102637402B1 - 게놈 내 특정 유전자좌에 단백질을 유도하기 위한 조성물 및 방법 - Google Patents

게놈 내 특정 유전자좌에 단백질을 유도하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR102637402B1
KR102637402B1 KR1020187001436A KR20187001436A KR102637402B1 KR 102637402 B1 KR102637402 B1 KR 102637402B1 KR 1020187001436 A KR1020187001436 A KR 1020187001436A KR 20187001436 A KR20187001436 A KR 20187001436A KR 102637402 B1 KR102637402 B1 KR 102637402B1
Authority
KR
South Korea
Prior art keywords
lys
leu
glu
ile
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187001436A
Other languages
English (en)
Korean (ko)
Other versions
KR20180036696A (ko
Inventor
에릭 오스터텍
쩨뗀 예시
시앙홍 리
Original Assignee
포세이다 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포세이다 테라퓨틱스, 인크. filed Critical 포세이다 테라퓨틱스, 인크.
Publication of KR20180036696A publication Critical patent/KR20180036696A/ko
Application granted granted Critical
Publication of KR102637402B1 publication Critical patent/KR102637402B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020187001436A 2015-06-17 2016-06-16 게놈 내 특정 유전자좌에 단백질을 유도하기 위한 조성물 및 방법 Active KR102637402B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562181162P 2015-06-17 2015-06-17
US62/181,162 2015-06-17
PCT/US2016/037922 WO2016205554A1 (en) 2015-06-17 2016-06-16 Compositions and methods for directing proteins to specific loci in the genome

Publications (2)

Publication Number Publication Date
KR20180036696A KR20180036696A (ko) 2018-04-09
KR102637402B1 true KR102637402B1 (ko) 2024-02-15

Family

ID=56292934

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187001436A Active KR102637402B1 (ko) 2015-06-17 2016-06-16 게놈 내 특정 유전자좌에 단백질을 유도하기 위한 조성물 및 방법

Country Status (11)

Country Link
US (2) US11473082B2 (enExample)
EP (2) EP3310909B1 (enExample)
JP (3) JP2018521689A (enExample)
KR (1) KR102637402B1 (enExample)
CN (1) CN108026519A (enExample)
AU (2) AU2016278226B2 (enExample)
CA (1) CA2989827C (enExample)
DK (1) DK3310909T3 (enExample)
ES (1) ES2886599T3 (enExample)
PT (1) PT3310909T (enExample)
WO (1) WO2016205554A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2891510C (en) 2012-11-16 2022-10-18 Transposagen Biopharmaceuticals, Inc. Site-specific enzymes and methods of use
KR102630014B1 (ko) 2014-10-01 2024-01-25 더 제너럴 하스피탈 코포레이션 뉴클레아제-유도 상동성-지정 복구의 효율 증가 방법
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
CA3036926C (en) * 2016-09-30 2022-05-31 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
CA3047313A1 (en) 2016-12-16 2018-06-21 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
CN117959418A (zh) 2017-03-13 2024-05-03 波赛达治疗公司 用于选择性消除和替换造血干细胞的组合物和方法
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
KR102523217B1 (ko) * 2017-07-11 2023-04-20 시그마-알드리치 컴퍼니., 엘엘씨 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용
WO2019135816A2 (en) * 2017-10-23 2019-07-11 The Broad Institute, Inc. Novel nucleic acid modifiers
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
WO2019126578A1 (en) * 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
EP3810764A2 (en) 2018-06-21 2021-04-28 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
CN110938658B (zh) * 2018-09-21 2023-02-07 中国科学院分子细胞科学卓越创新中心 一种抗体进化方法及其应用
WO2020077360A1 (en) 2018-10-12 2020-04-16 Poseida Therapeutics, Inc. Hematopoietic stem cell compositions, methods of making and method of use
AU2019401282A1 (en) 2018-12-20 2021-07-15 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
WO2020160481A1 (en) * 2019-02-01 2020-08-06 The General Hospital Corporation Targetable 3'-overhang nuclease fusion proteins
CN113677694B (zh) * 2019-04-09 2025-01-10 国立研究开发法人科学技术振兴机构 核酸结合蛋白
JP2022536364A (ja) 2019-06-13 2022-08-15 ザ ジェネラル ホスピタル コーポレイション 操作されたヒト内在性ウイルス様粒子および細胞への送達のためのその使用方法
CN114761424B (zh) 2019-09-05 2025-09-19 波赛达治疗公司 同种异体细胞组合物和使用方法
CN115135672A (zh) 2019-12-20 2022-09-30 波赛达治疗公司 抗muc1组合物和使用方法
WO2021183795A1 (en) 2020-03-11 2021-09-16 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
WO2022020800A2 (en) 2020-07-24 2022-01-27 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
WO2022087148A1 (en) 2020-10-21 2022-04-28 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
US20230399660A1 (en) * 2020-10-23 2023-12-14 Altius Institute For Biomedical Sciences Cell Permeable Proteins for Genome Engineering
CN112750498B (zh) * 2020-12-30 2022-06-24 同济大学 靶向逆转录引物结合位点从而抑制hiv病毒复制的方法
JP2024507846A (ja) 2021-02-23 2024-02-21 ポセイダ セラピューティクス，インコーポレイティド 核酸の送達のための組成物及び方法
WO2022182797A1 (en) 2021-02-23 2022-09-01 Poseida Therapeutics, Inc. Genetically modified induced pluripotent stem cells and methods of use thereof
EP4398915A1 (en) 2021-09-09 2024-07-17 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
CA3233506A1 (en) 2021-10-04 2023-04-13 Joseph S. LUCAS Transposon compositions and methods of use thereof
AU2023210287A1 (en) 2022-01-21 2024-09-05 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
US20250171809A1 (en) 2022-02-23 2025-05-29 Poseida Therapeutics, Inc. Genetically modified cells and methods of use thereof
WO2023209649A1 (en) * 2022-04-29 2023-11-02 Seqirus, Inc. Method of dna linearization
WO2024007010A2 (en) * 2022-06-30 2024-01-04 Demeetra Agbio, Inc. Gene editing compositions and methods of use thereof
JP2025534904A (ja) 2022-10-21 2025-10-21 キージーン ナムローゼ フェンノートシャップ 修飾ｒｎａによる植物細胞へのｒｎａトランスフェクション
EP4623073A2 (en) 2022-11-21 2025-10-01 Iovance Biotherapeutics, Inc. Methods for assessing proliferation potency of gene-edited t cells
JP2025539816A (ja) 2022-11-21 2025-12-09 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の増幅のための２次元プロセス及びそれからの治療法
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2024121354A1 (en) 2022-12-08 2024-06-13 Keygene N.V. Duplex sequencing with covalently closed dna ends
KR20250162510A (ko) 2023-01-20 2025-11-18 포세이다 테라퓨틱스, 인크. 리피도이드 화합물 및 관련 조성물 및 용도
EP4651943A1 (en) 2023-01-20 2025-11-26 Poseida Therapeutics, Inc. Lipidoid compounds and related compositions and uses
AU2024224169A1 (en) 2023-02-21 2025-08-21 Poseida Therapeutics, Inc. Compositions and methods for genome editing
IL322767A (en) 2023-02-21 2025-10-01 Poseida Therapeutics Inc Genome editing vehicles and methods
WO2024209000A1 (en) 2023-04-04 2024-10-10 Keygene N.V. Linkers for duplex sequencing
WO2024238829A1 (en) 2023-05-17 2024-11-21 Poseida Therapeutics, Inc. Compositions targeting hbg1 and hbg2 and methods of use thereof
WO2025049925A2 (en) 2023-09-01 2025-03-06 Poseida Therapeutics, Inc. Lipidoid compounds and related compositions and uses
WO2025096980A1 (en) * 2023-11-02 2025-05-08 Poseida Therapeutics, Inc. Compositions targeting klkb1 and methods of use thereof
WO2025160432A1 (en) 2024-01-26 2025-07-31 Poseida Therapeutics, Inc. Methods and compositions for enhancing in vivo persistence and potency of cell therapy
WO2025171237A1 (en) 2024-02-08 2025-08-14 Poseida Therapeutics, Inc. Lipidoid compounds and related compositions and uses
WO2025221789A1 (en) 2024-04-16 2025-10-23 Poseida Therapeutics, Inc. Compositions and methods for use in car/tcr cell therapies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140298505A1 (en) * 2011-06-07 2014-10-02 Ralf Kühn Protein having nuclease activity, fusion proteins and uses thereof
US20150044772A1 (en) * 2013-08-09 2015-02-12 Sage Labs, Inc. Crispr/cas system-based novel fusion protein and its applications in genome editing

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5380831A (en) 1986-04-04 1995-01-10 Mycogen Plant Science, Inc. Synthetic insecticidal crystal protein gene
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5529774A (en) 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
TW261517B (enExample) 1991-11-29 1995-11-01 Mitsubishi Shozi Kk
US5911983A (en) 1992-06-26 1999-06-15 University Of Pittsburgh Gene therapy for Gaucher disease using retroviral vectors
ATE301201T1 (de) 1993-06-07 2005-08-15 Vical Inc Für die gentherapie verwendbare plasmide
US5645829A (en) 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US5639642A (en) 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
US7285416B2 (en) 2000-01-24 2007-10-23 Gendaq Limited Regulated gene expression in plants
DE19524720A1 (de) 1995-07-12 1997-01-16 Hoechst Ag Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3"
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
JP4216350B2 (ja) 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター
US5789147A (en) 1994-12-05 1998-08-04 New York Blood Center, Inc. Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood
US5869040A (en) 1995-06-07 1999-02-09 Biogen, Inc Gene therapy methods and compositions
US5928914A (en) 1996-06-14 1999-07-27 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Methods and compositions for transforming cells
AU5209399A (en) 1998-07-10 2000-02-01 Cornell Research Foundation Inc. Recombinant constructs and systems for secretion of proteins via type iii secretion systems
CA2246005A1 (en) 1998-10-01 2000-04-01 Hsc Research And Development Limited Partnership Hybrid genes for gene therapy in erythroid cells
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
AU6045900A (en) 1999-05-25 2000-12-12 Panorama Research, Inc. Interaction-activated proteins
ATE353361T1 (de) 2000-04-28 2007-02-15 Sangamo Biosciences Inc Gezielten modifikation der chromatinstruktur
CA2435394C (en) 2001-01-22 2018-01-09 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
JP4130955B2 (ja) * 2001-06-05 2008-08-13 真寛 平岡 有酸素条件下の細胞内でタンパク質を不安定化させるポリペプチドとそれをコードするｄｎａ
US20030138850A1 (en) 2001-10-18 2003-07-24 Ekkehard Mossner Selecting for antibody-antigen interactions in bacteria cells by employing a protein fragment complementation assay
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
WO2009095742A1 (en) 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
AU2003218382B2 (en) 2002-03-21 2007-12-13 Sangamo Therapeutics, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
GB0226729D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
US8021849B2 (en) 2004-11-05 2011-09-20 Siemens Healthcare Diagnostics Inc. Methods and kits for the determination of sirolimus in a sample
US20060252140A1 (en) 2005-04-29 2006-11-09 Yant Stephen R Development of a transposon system for site-specific DNA integration in mammalian cells
US7790379B2 (en) 2005-05-19 2010-09-07 Universite De Geneve Mapping of proteins along chromatin by chromatin cleavage
WO2007060495A1 (en) 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
JP2007159512A (ja) 2005-12-15 2007-06-28 Institute Of Physical & Chemical Research Ｉｉｓ型制限酵素を用いる翻訳終止コドンの除去方法
US20100015661A1 (en) 2006-04-21 2010-01-21 Mab-Factory Gmbh Antibody-rnase-conjugate
WO2008130629A2 (en) 2007-04-19 2008-10-30 Codon Devices, Inc. Engineered nucleases and their uses for nucleic acid assembly
CA2698727A1 (en) 2007-09-17 2009-03-26 Affomix Corporation Increasing specificity in a scfv screen using dual bait reporters
JP2012518398A (ja) 2009-02-24 2012-08-16 グラクソ グループ リミテッド 抗原結合性構築物
AU2010260476A1 (en) 2009-03-11 2011-10-13 Wyeth Llc Methods of purifying small modular immunopharmaceutical proteins
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
CN103025344B (zh) 2010-05-17 2016-06-29 桑格摩生物科学股份有限公司 新型dna-结合蛋白及其用途
KR101556359B1 (ko) * 2011-01-03 2015-10-01 주식회사 툴젠 디자인된 tal 이펙터 뉴클레아제를 통한 게놈 엔지니어링
BR112013017363A2 (pt) 2011-01-06 2016-08-30 Complix Sa biblioteca de alphabody de cadeia única, mistura de bibliotecas de alphabody, ácido nucleico ou biblioteca de vetor, biblioteca de células hospedeiras, uso de uma biblioteca de alphabody de cadeia única, método para a produção de uma biblioteca de alphabody de cadeia única, método para a produção de um ou mais polipeptídeos de alphabody de cadeia única, polipeptíceo de alphabody de cadeia única, ácido nucleico, vetor e célula hospedeira
US9499592B2 (en) 2011-01-26 2016-11-22 President And Fellows Of Harvard College Transcription activator-like effectors
KR101982360B1 (ko) 2011-04-05 2019-05-24 셀렉티스 콤팩트 tale-뉴클레아제의 발생 방법 및 이의 용도
EP2522726A1 (en) 2011-05-12 2012-11-14 Fundació Privada Centre de Regulació Genòmica (CRG) Zinc finger nucleases for p53 editing
US20140201858A1 (en) 2011-05-17 2014-07-17 Transposagen Biopharmaceuticals, Inc Methods for site-specific genetic modification in stem cells using xanthomonas tal nucleases (xtn) for the creation of model organisms
EP2718446A2 (en) 2011-06-07 2014-04-16 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Improved recombination efficiency by inhibition of nhej dna repair
BR112014014105B1 (pt) 2011-12-16 2023-10-10 Targetgene Biotechnologies Ltd Método para modificar um sítio-alvo predeterminado no interior de um ácido nucleico genômico ou organelar alvo em uma célula hospedeira eucariótica por um complexo núcleoproteína
US20130274129A1 (en) 2012-04-04 2013-10-17 Geneart Ag Tal-effector assembly platform, customized services, kits and assays
US9498538B2 (en) 2012-05-21 2016-11-22 Massachusetts Institute Of Technology Translocation of non-natural chemical entities through anthrax protective antigen pore
SI3401400T1 (sl) * 2012-05-25 2019-10-30 Univ California Postopki in sestavki za RNA usmerjeno modifikacijo tarčne DNA in za RNA usmerjeno modulacijo prepisovanja
US9181535B2 (en) * 2012-09-24 2015-11-10 The Chinese University Of Hong Kong Transcription activator-like effector nucleases (TALENs)
JP6454643B2 (ja) 2012-10-26 2019-01-16 フリーイェ・ユニヴェルシテイト・ブリュッセルＶｒｉｊｅ Ｕｎｉｖｅｒｓｉｅｉｔ Ｂｒｕｓｓｅｌ 血友病の肝臓指向性遺伝子治療のためのベクター並びにその方法及び使用
CA2891510C (en) 2012-11-16 2022-10-18 Transposagen Biopharmaceuticals, Inc. Site-specific enzymes and methods of use
EP3138911B1 (en) * 2012-12-06 2018-12-05 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
EP2931898B1 (en) 2012-12-12 2016-03-09 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
SG11201609211VA (en) 2014-03-05 2016-12-29 Nat Univ Corp Univ Kobe Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same
JP2017518082A (ja) * 2014-06-17 2017-07-06 ポセイダ セラピューティクス， インコーポレイテッド ゲノム中の特異的遺伝子座にタンパク質を指向させるための方法およびその使用
EP3158070A1 (en) 2014-06-17 2017-04-26 Poseida Therapeutics, Inc. Methods and compositions for in vivo non-covalent linking
CN104450785A (zh) 2014-12-08 2015-03-25 复旦大学 使用编码靶向核酸内切酶附着体载体的基因组编辑方法及试剂盒

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140298505A1 (en) * 2011-06-07 2014-10-02 Ralf Kühn Protein having nuclease activity, fusion proteins and uses thereof
US20150044772A1 (en) * 2013-08-09 2015-02-12 Sage Labs, Inc. Crispr/cas system-based novel fusion protein and its applications in genome editing

Also Published As

Publication number Publication date
EP3929286A1 (en) 2021-12-29
ES2886599T3 (es) 2021-12-20
US20230257737A1 (en) 2023-08-17
JP7170090B2 (ja) 2022-11-11
JP2018521689A (ja) 2018-08-09
US20180187185A1 (en) 2018-07-05
HK1253508A1 (zh) 2019-06-21
AU2016278226B2 (en) 2021-08-12
WO2016205554A1 (en) 2016-12-22
AU2016278226A1 (en) 2018-01-25
DK3310909T3 (da) 2021-09-13
CN108026519A (zh) 2018-05-11
KR20180036696A (ko) 2018-04-09
JP2021112211A (ja) 2021-08-05
AU2021250992A1 (en) 2021-11-11
EP3310909B1 (en) 2021-06-09
US11473082B2 (en) 2022-10-18
PT3310909T (pt) 2021-09-09
EP3310909A1 (en) 2018-04-25
JP2021182942A (ja) 2021-12-02
CA2989827C (en) 2024-09-10
AU2021250992B2 (en) 2023-09-28
CA2989827A1 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
AU2021250992B2 (en) Compositions and methods for directing proteins to specific loci in the genome
KR102606929B1 (ko) 동족 항원과 t-세포 수용체 상호작용의 발견 및 특징규명을 위한 조작된 2-부분 세포 디바이스
CN108715861B (zh) 一种碱基编辑工具及其应用
KR102516695B1 (ko) 단백질 내로의 비-천연 아미노산의 혼입
KR20150125994A (ko) 세포 발현 시스템
KR102584628B1 (ko) T-세포 수용체, t-세포 항원 및 이들의 기능성 상호작용의 식별 및 특징규명을 위한 조작된 다성분 시스템
CN101553506A (zh) Lingo结合分子及其制药用途
CN108753823B (zh) 利用碱基编辑技术实现基因敲除的方法及其应用
KR20080031024A (ko) 폴리단백질, 프로단백질 및 단백질분해를 사용한 ｓＯＲＦ작제물 포함 다중 유전자 발현 및 방법
KR20080031296A (ko) Ｐｓｍａ 항체-약물 접합체
JP7684271B2 (ja) Ｔ細胞レセプター及びｔ細胞抗原の同定及び特徴決定のための遺伝子操作された多成分システム
AU2017352591B2 (en) A two-part device for T-cell receptor synthesis and stable genomic integration to TCR-presenting cells
CN110437334B (zh) 全人源抗金黄色葡萄球菌α-溶血素重组抗体
CN113583096B (zh) SARS-CoV-2 Spike蛋白受体结合域二聚体及其应用
CN108531458A (zh) 治疗肿瘤的基因工程自然杀伤细胞产品
US6468754B1 (en) Vector and method for targeted replacement and disruption of an integrated DNA sequence
CN116887854A (zh) Omni-103 crispr核酸酶
KR20200088805A (ko) 게놈-편집 조류
KR20230142740A (ko) Omni-103 crispr 뉴클레아제
CN111727244B (zh) 循环肿瘤细胞的通用检测探针
HK40038630A (en) Probe for universal detection of circulating tumor cells
HK40038630B (zh) 循环肿瘤细胞的通用检测探针

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601